Hospital del Mar Research Institute Hospital del Mar Research Institute

News / Press release

  • 28/01/2014 - Press release

    Measuring waist circumference would improve the detection of children and adolescents with cardiometabolic risk

    A study led by researchers from IMIM (Hospital del Mar Medical Research Institute) and published in the journal PlosOne concludes that including waist circumference measurements in clinical practice, together with the traditional height and weight measurements, would make it easier to detect children and adolescents with cardiometabolic risk, i.e. those with a higher predisposition to suffer from arteriosclerosis or type 2 diabetes. This study is the first of its kind in Spain on abdominal obesity in children and adolescents, one of the most important risk factors associated to this disorder, which has increased in recent years.

    Més informació "Measuring waist circumference would improve the detection of children and adolescents with cardiometabolic risk"

  • 14/11/2013 - Press release

    Researchers from IMIM describe a new function of two molecules involved in metastasis

    Researchers from IMIM (Hospital del Mar Medical Research Institute) lead by Dr. Sandra Peiró have described a new function for two key molecules involved in tumor progression. Transcription factor SNAIL1 and enzyme LOXL2 are essential to Epithelial-Mesenchymal Transition (EMT); meaning the process by which tumor cells are able to move and reach other tissues. The study has been published in the Molecular Cell Journal and places enzyme LOXL2 as a possible therapeutic target to treat cancers such as breast, lung or skin cancer. Transcription factors are proteins that regulate gene expression. They activate or deactivate a gene’s function. Researchers at IMIM have studied the function of one of these transcription factors, Snail1, in mouse cells during the Epithelial-Mesenchymal Transition (EMT). Sandra Peiró, a researcher from the IMIM Research Group on Epithelial-Mesenchymal Transition and Tumor Progression explains: “EMT is a process consisting of converting epithelial cells, the ones covering the internal and external surfaces of the body, into what are known as mesenchymal cells. In this process, the cells acquire a series of new characteristics that enable them to migrate and resist apoptosis (programmed cell death), self-regenerate and, finally, invade neighboring tissues and reach other areas of the body. When this process occurs at the tumor epithelial cells, the resulting mesenchymal cells can migrate and generate metastases”.

    Més informació "Researchers from IMIM describe a new function of two molecules involved in metastasis"

  • 28/10/2013 - Press release

    New statistic model forecasts the effect of tobacco consumption on childhood asthma

    A scientific study recently published on International Journal of Statistics in Medical Research states that tobacco consumption must be decreased by 15% in Spain, particularly at home, in order to reduce the number of childhood asthma cases. The research is signed by professors Toni Monleón-Getino and Martín Ríos, from the Department of Statistics of the UB, and experts Oriol Vall, Carme Puig, Òscar Garcia-Algar and Antonella Chiandetti, members of the Childhood and Environment Research Group of the Hospital del Mar Medical Research Institute (IMIM). Asthma is the most common chronic illness during childhood and adolescence in industrialized countries. Several factors have been proposed to explain asthma. It affects between 10% and 17% of children and teenagers in Spain. There is no treatment to cure this illness which may decrease considerably patients’ quality of life. Although its prevalence has been increasing over the last 40 years in many countries, no statistical or simulation model existed to forecast the evolution of childhood asthma in Europe.

    Més informació "New statistic model forecasts the effect of tobacco consumption on childhood asthma"

  • 26/09/2013 - Press release

    Intestinal mucus has anti-inflammatory functions

    Researchers at Institut Hospital del Mar d’Investigacions Mèdiques (IMIM) in Barcelona, in collaboration with the Icahn School of Medicine at Mount Sinai in New York and other U.S. Institutions, have found that intestinal mucus not only acts as a physical barrier against commensal bacteria and dietary antigens, but also prevents the onset of inflammatory reactions against these agents. This fundamental property of mucus was unknown until now and its discovery could potentially improve the life of people suffering from inflammatory bowel disease. Mucus is a colloidal gel produced by glands present in our mucosal surfaces, including the intestine. "Our body produces on average a liter of mucus every day. Despite its abundance, mucus has been poorly studied and thus very little is known about its composition, synthesis and functional properties. Part of the problem may be that mucus is traditionally viewed as a symbol of disease and thus represents an antivalue" explains Dr. Andrea Cerutti, ICREA Research Professor, coordinator of the research group in B Cell Biology at IMIM, Professor of Medicine at Mount Sinai and responsible for the study.

    Més informació "Intestinal mucus has anti-inflammatory functions"

  • 19/09/2013 - Press release

    Mental disorders are responsible for 17% of disability worldwide

    Jordi Alonso, director of the Epidemiology and Public Health Programme of the IMIM-Hospital del Mar Research Institute in Barcelona, is the scientific coordinator of the European Study of the Epidemiology of Mental Disorders (ESEMeD), a component of the surveys. Mental disorders are a great burden, for individuals as much as for society. It is therefore important to know the direct costs of offering adequate attention as well as the social cost engendered by not offering it. With this objective the WHO carries out worldwide mental health surveys in order to portray a complete portrait of the situation of mental disorders in the world.

    Més informació "Mental disorders are responsible for 17% of disability worldwide"

  • 11/07/2013 - Press release

    Important advance in the fight against skin cancer

    Researchers from the Hospital del Mar Medical Research Institute (IMIM), lead by Lluís Espinosa, have identified a new function of the IkBa protein that is key in the development of squamous-cell carcinoma, a type of skin cancer. The study has been published in the prestigious journal Cancer Cell and provides a new tool for the diagnosis of the disease and, in the future, will enable the identification of novel therapeutic targets to treat this type of cancer. Until now, the only known function of the protein IkBa was in the cytoplasm where it inhibits the NF-kB factor, a protein complex that is involved in the immune response. Now we have discovered that in the nucleus of keratinocytes, the typical skin cells, and also in the nucleus of fibroblasts, there is a different form of IkBa that results from its binding to another molecule called Sumo (leading to the Sumo-IkBa protein) that had been previously observed by other groups, but no function had been adscribed.

    Més informació "Important advance in the fight against skin cancer"

  • 17/04/2013 - Press release

    AICR, one of the most important cancer research associations in the world, to finance two IMIM projects

    The Association for International Cancer Research (AICR) has granted Dr. Anna Bigas, coordinator of the IMIM stem cells and cancer research group, 199,867 GBP (231,491 euros) for the three year project “Notch1 and B-Catenin Crosstalk in T-cell Acute Lymphoblastic Leukaemia”, and Dr. Sandra Peiró, investigator for the IMIM epithelial-mesenchymal transition in tumor development research group, 167,495 GBP (193,955 euros) for the project “Heterochromatin reorganization during the EMT process is controlled by Snail1 transcription factor” also due to take place over three years. AICR is a charitable organisation which has for the past 32 years provided funding for investigators with high level cancer research projects, regardless of their country, in order to support basic or translational research into the causes, mechanisms, diagnosis, treatment and prevention of cancer. The Association has a Scientific Advisory Committee which completes a two-yearly selection of projects using  strict quality criteria, as only 7 – 8 % of all applications are selected. It is currently supporting 182 ongoing projects around the world.

    Més informació "AICR, one of the most important cancer research associations in the world, to finance two IMIM projects"

  • 20/03/2013 - Press release

    A step forward in the treatment of chronic urticaria

    An international study involving Dr. Ana Giménez Arnau, a dermatologist at the Hospital del Mar and researcher with the group conducting research on inflammatory dermatological diseases at the IMIM (Hospital del Mar Medical Research Institute) has concluded that a drug normally used to treat severe bronchial asthma caused by allergies (Omalizumab) rapidly eliminates the symptoms of spontaneous chronic urticaria, a development that it is expected will significantly improve the quality of life of chronic urticaria sufferers. Spontaneous chronic urticaria, one of the most common skin diseases, consists of an abrupt reaction that results in hives or stains of different shapes and sizes on the surface of the skin that grow and produce a very intense itch. Sufferers can develop dozens of hives each day for months or years. When the condition persists for more than 6 weeks, it is referred to as chronic urticaria and can last between approximately 5 and 10 years, adversely affecting the quality of life of the sufferer in both physical and emotional terms. The research, which has consisted of an international Phase III clinical trial conducted across several centres of research, has run for 7 months and involved 323 patients from different countries. These patients have an average age of 42 and for the most part are women (76%), a description that accurately reflects the profile of patients with chronic urticaria.

    Més informació "A step forward in the treatment of chronic urticaria"

  • 26/02/2013 - Press release

    BiblioPRO: first virtual library specializing in Spanish instruments for the assessment of health-related quality of life

    The Patient-Reported Outcomes (PRO) have become significant health and quality of life indicators in clinical and epidemiological research. The health reported by patients has such an important predictive power as mortality, services demand and health costs. BiblioPRO is the first virtual library in the world specialized in these health-related quality of life instruments, the PROs, in Spanish, classified and documented following a conceptual and rigorous classification form. It includes instruments designed originally in Spanish, as well as cultural adaptations developed by Spain and Latin America, because most of these instruments have been carried out in English-speaking countries. BiblioPRO has been developed by the research group on health services of IMIM, who have been the organizers of the I Jornada Científica BiblioPRO

    Més informació "BiblioPRO: first virtual library specializing in Spanish instruments for the assessment of health-related quality of life"

  • 14/02/2013 - Press release

    Catalan universities and research centres to create Bioinformatics Barcelona (BiB), a platform to promote training, research, and the transfer of technology in bioinformatics

    The vice-chancellors of three Catalan universities and representatives of ten biological and biomedical research institutes, together with the Barcelona Supercomputing Center – Centro Nacional de Supercomputación (BSC-CNS) and BioCat, this morning signed an agreement to create Bioinformatics Barcelona (BiB), a platform which it is hoped will turn the Barcelona area into an international point of reference in the field of bioinformatics through cooperation between universities, centres of research, and other public and private entities.

    Més informació "Catalan universities and research centres to create Bioinformatics Barcelona (BiB), a platform to promote training, research, and the transfer of technology in bioinformatics"

Contact

Servei de Comunicació:
Marta Calsina Freixas(ELIMINAR)

Tel:
(+34) 93 316 06 80

Doctor Aiguader, 88
08226 Barcelona

© Institut Hospital del Mar
d'Investigacions Mèdiques
Legal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact